Market Overview

INmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, Ph.D., Chairing Sessions at International Society of Cell and Gene Therapy (ISCT) European Regional Meeting

Share:

LA JOLLA, Calif. , Sept. 12, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – INmune Bio, Inc., an immunotherapy company developing treatments to reprogram the patient's innate immune system, today announced that Co-Founder and Chief Scientific Officer Mark Lowdell, Ph.D., is co-hosting and chairing two sessions at the International Society of Cell and Gene Therapy (ISCT) European Regional Meeting.

"I'm delighted to be able to speak in front of leaders and visionaries in the immunotherapy space at a conference where we can help make a difference by partnering with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives worldwide," said Dr. Lowdell. "I am a tremendous supporter of ISCT, an organization that has been bringing groups together, spanning the international cell and gene therapy community. I believe the organization is the pre-eminent scientific society in the field of translational cell and gene therapy."

Dr. Lowdell's highly touted research projects have involved clinical trials of natural killer (NK) cell immunotherapies in blood cancers, paralleling the track that INmune Bio is currently involved with. His work as the professor of Cell & Tissue Therapeutics focuses on targeting human NK cells to improve cancer immunotherapy. He is a professor and consultant scientist who has been called upon to speak at prestigious conferences across the world.

In Dr. Lowdell's first session, titled "Cancer Immunotherapy: Advances in Cancer Cell Therapy – Balancing Toxicity and Efficacy," the panel will detail recent developments in the innate immunotherapy space, with a particular focus on NK and gamma/delta-T cells. They will also discuss the latest advancements of cellular anti-tumor therapies and associated toxicities and compare the advantages and disadvantages of different cellular products.

The second session Dr. Lowdell will chair, titled "Manufacturing: Closing the Process," will highlight the importance of engineering closed processes in advanced therapy medicinal products (ATMP) early in development in terms of early phase trials and market access. It will explain the importance of process developments done during pre-clinical work-up in driving down cost and complexity of early phase trials and how small registration trials have decreased optimization time for manufacturing improvements in Phase 1 and 2 trials.

Taking place in Florence, Italy, the conference provides an opportunity for industry leaders in cell and gene therapy to share research and exchange ideas. It draws doctors, laboratory professionals, clinicians, scientists, industry personnel from cell therapy companies, and many more experts from across Europe.

Dr. Lowdell is the past Regional Vice President of Europe on the Global Executive Committee of the ISCT board.

Details of the sessions are as follows:
Session Title: Cancer Immunotherapy: Advances in Cancer Cell Therapy – Balancing Toxicity and Efficacy
Date: September 13, 2018
Location: Firenze Fiera Congress and Exhibition Center, Florence, Italy

Session Title: Manufacturing: Closing the Process
Date: September 13, 2018
Location: Firenze Fiera Congress and Exhibition Center, Florence, Italy

About ISCT
ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. ISCT is the only group focused on pre-clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practise and product. ISCT is incorporated as a not for profit organization, 501(c)(3) in Washington DC.

About INmune Bio, Inc.
INmune Bio Inc. is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Our drug candidates, INKmuneTM and INB03, can be used alone or with conventional therapies to help eliminate disease in a wide variety of cancers. They can also boost the effectiveness of other immunotherapies designed to enhance immune response to specific tumors.

The development of new immunotherapies is revolutionizing cancer care. INmune Bio is at the forefront of that revolution with novel products that take the brakes off of the most powerful weapon in the fight against cancer: the patient's immune system.

For more information, please visit www.inmunebio.com.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
dmoss@inmunebio.com

Media Contact:
Antenna Group
Nechama Feuerstein
(201) 373-2228
inmunebio@antennagroup.com

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

inmunebio-PNG.png

View Comments and Join the Discussion!